Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SVRA, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Molgramostim | Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 · NCT06431776 | Recruiting |
| Molgramostim Open-label | Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 · NCT04544293 | Active not recruiting |
| Vancomycin inhalation powder | MRSA | Phase 3 · NCT03181932 | Completed |
| Antimycobacterial regimen | Mycobacterium Infections, Nontuberculous | Phase 2 · NCT03421743 | Completed |
| Inhaled molgramostim | Mycobacterium Infections, Nontuberculous | Phase 2 · NCT03421743 | Completed |
| Molgramostim nebulizer solution | Mycobacterium Infections, Nontuberculous | Phase 2 · NCT03597347 | Terminated |
| Vancomycin hydrochloride inhalation powd | Cystic Fibrosis | Phase 2 · NCT01746095 | Completed |
| AeroVanc | Healthy | Phase 1 · NCT01537666 | Completed |
| IV vancomycin hydrochloride | Healthy | Phase 1 · NCT01537666 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SVRA holds $173M in cash and short-term investments (as of Jun 30, 2026) and burns about $31.4M/quarter from operations, an estimated runway of 16.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SVRA files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SVRA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →